Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation

MLA

Quinquenel, Anne, et al. “Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation.” Blood, vol. 140, no. Supplement 1, Nov. 2022, pp. 7007–09. EBSCOhost, https://doi.org/10.1182/blood-2022-159678.

APA

Quinquenel, A., Letestu, R., Le Garff-Tavernier, M., Subtil, F., Aurran-Schleinitz, T., Laribi, K., Cymbalista, F., Levy, V., Simon, L., Roos-Weil, D., Leblond, V., Dilhuydy, M.-S., Dartigeas, C., Tomowiak, C., Guieze, R., Tournilhac, O., Ferrant, E., de Guibert, S., Feugier, P., … Michallet, A.-S. (2022). Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation. Blood, 140(Supplement 1), 7007–7009. https://doi.org/10.1182/blood-2022-159678

Chicago

Quinquenel, Anne, Rémi Letestu, Magali Le Garff-Tavernier, Fabien Subtil, Therese Aurran-Schleinitz, Kamel Laribi, Florence Cymbalista, et al. 2022. “Preliminary Results of the Filo Phase 2 Trial for Untreated Fit Patients with Intermediate Risk Chronic Lymphocytic Leukemia Comparing Ibrutinib Plus Venetoclax (IV) Versus FCR: Results of the Month 15 MRD Evaluation.” Blood 140 (Supplement 1): 7007–9. doi:10.1182/blood-2022-159678.